Pfizer Predicts Exubera, Chantix Favorable Reimbursement Despite Delays
Executive Summary
Pfizer's Chantix and Exubera are being favorably received by payers in early formulary discussions, Senior VP-Global Pharmaceutical Finance Peter Brandt said during the company's second quarter earnings call July 20
You may also be interested in...
As Pfizer Closes Door On Exubera, Has Window Opened For Others?
Pfizer's decision to terminate its Exubera program - the first inhaled insulin product to hit the market - could provide an opportunity for other drug makers looking to step into the market, especially those prepared to address obstacles illuminated by Pfizer
As Pfizer Closes Door On Exubera, Has Window Opened For Others?
Pfizer's decision to terminate its Exubera program - the first inhaled insulin product to hit the market - could provide an opportunity for other drug makers looking to step into the market, especially those prepared to address obstacles illuminated by Pfizer
Pfizer Plans Exubera “Full Court Press”’ In 2007 After 2006 Stumbles
Pfizer is finally ramping up for a full-scale launch of the inhaled insulin Exubera - targeting primary care physicians and consumers - over one year after the drug was approved by FDA